In recent years, rapid rates of economic growth in emerging markets have been prompting the development of healthcare infrastructures. This factor, plus an increasing awareness of health and healthcare, are spurring demand for medical care and testing. At the same time, healthcare needs in advanced countries are growing more diverse, owing to efforts to curtail costs and respond to aging populations, as well as to making inroads in preventive medicine and personalized medicine.
Since the time of its establishment, Sysmex has concentrated on its mainstay field of hematology, which involves the analysis of red blood cells, white blood cells, platelets and other blood components. Through these efforts, the Company has acquired the leading share of the global hematology market.
The XN-Series, which launched in 2011, helps to enhance clinical value by providing a low-WBC mode2 and body fluid mode3, as well as providing reticulocyte hemoglobin equivalent4.
This new addition to the XN-Series carries forth the functionality and operability that have earned the XN-Series a strong reputation throughout the world. This model features increased compactness by internalizing the pneumatic power source and miniaturizing detectors. The result provides one of the most compact instruments in its class. In addition to five-part white blood cell differentiation, the XN-L also conducts automated reticulocyte analysis using the fluorescent flow cytometry method.
As well as being compact, the XN-L series offers high levels of performance and operability, which customers have come to expect from Sysmex. The model is designed to meet a diverse range of needs. Aimed primarily for use in small and medium-sized healthcare facilities, the XN-L series is also suited for emergency laboratories at large-scale institutions that have already adopted the XN-Series.
The new series also is compatible with the Sysmex Network Communication Systems (SNCS®5), which allows online monitoring of the instrument's operating conditions. This function enables real-time external quality control and web-based information delivery, helping to pre-empt sudden malfunctions.
Additionally, this new product can help meet the demand in emerging markets for flagging blood cell shape changes that occurs in cases of malaria, one of the world's most deadly infectious diseases.
Going forward, Sysmex aims to meet increasingly sophisticated needs in emerging markets, including China and other parts of Asia, that are slated for further growth by providing high-value-added testing.